Form 4: Dar Zavain Acquires Recursion Pharmaceuticals Stock

Director Dar Zavain acquired 4,902 shares of Recursion Pharmaceuticals Class A Common Stock under the company's Outside Director Compensation Policy.

Summary

• Dar Zavain, a Director at Recursion Pharmaceuticals, Inc., acquired 4,902 shares of Class A Common Stock on April 1, 2026.
• These shares were issued under the company's Outside Director Compensation Policy.
• Following this transaction, Dar Zavain beneficially owns 147,231 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine stock acquisition by a director under a compensation policy, with no immediate indication of significant positive or negative company performance.

Positives

• Director acquisition of shares can signal confidence in the company's future prospects.
• The acquisition was made under a pre-established compensation policy, indicating a standard practice rather than a discretionary purchase.

Future Outlook

No specific forward-looking statements or guidance were provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that Form 4 filings, which report changes in beneficial ownership by insiders, are standard disclosures. Director acquisitions, while not always indicative of future stock performance, can be interpreted as a positive signal of internal confidence.

Stakeholder Impact

• Shareholders: The acquisition by a director may be viewed positively as a sign of internal confidence, though the shares were acquired under a compensation plan.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Acquisition, Director Compensation, Recursion Pharmaceuticals, RXRX